Key Points
- CEO sold 36,500 shares — Joseph Oliveto disposed of 36,500 shares on April 16 at an average $2.26 under a pre-arranged Rule 10b5-1 plan (≈$82,490), leaving him with 446,244 shares, a 7.56% reduction valued at about $1.01M.
- MIST opened at $2.04 and was down 2.9%, with a market cap of ~$240M and a 12‑month range of $0.88–$3.06; analysts hold a consensus Moderate Buy rating with a $7.50 target amid mixed individual ratings.
- In the most recent quarter Milestone reported EPS of ($0.16), beating estimates of ($0.18) but reporting revenue of $1.44M versus $37.52M expected, and analysts forecast -0.64 EPS for the current fiscal year.
Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) CEO Joseph Oliveto sold 36,500 shares of the stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $2.26, for a total value of $82,490.00. Following the completion of the transaction, the chief executive officer directly owned 446,244 shares of the company's stock, valued at approximately $1,008,511.44. This represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Joseph Oliveto also recently made the following trade(s):
- On Monday, January 26th, Joseph Oliveto sold 34,523 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $1.93, for a total transaction of $66,629.39.
Milestone Pharmaceuticals Stock Down 2.9%
MIST stock opened at $2.04 on Tuesday. The company has a market cap of $240.05 million, a price-to-earnings ratio of -2.58 and a beta of 0.69. The company has a current ratio of 8.01, a quick ratio of 7.96 and a debt-to-equity ratio of 1.37. Milestone Pharmaceuticals Inc. has a 12 month low of $0.88 and a 12 month high of $3.06. The firm has a 50-day moving average of $1.65 and a two-hundred day moving average of $1.95.
Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last released its quarterly earnings data on Friday, March 20th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. The business had revenue of $1.44 million during the quarter, compared to analyst estimates of $37.52 million. As a group, analysts forecast that Milestone Pharmaceuticals Inc. will post -0.64 earnings per share for the current fiscal year.
Analyst Ratings Changes
MIST has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen downgraded Milestone Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, April 11th. Raymond James Financial initiated coverage on Milestone Pharmaceuticals in a research note on Friday, April 10th. They issued a "strong-buy" rating and a $6.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 target price on shares of Milestone Pharmaceuticals in a research note on Tuesday, January 6th. Finally, Zacks Research downgraded Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Milestone Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $7.50.
Read Our Latest Research Report on MIST
Institutional Trading of Milestone Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Propel Bio Management LLC increased its holdings in shares of Milestone Pharmaceuticals by 186.1% during the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company's stock worth $10,250,000 after buying an additional 3,333,333 shares during the last quarter. Orbimed Advisors LLC acquired a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter worth about $6,444,000. Simplify Asset Management Inc. increased its position in shares of Milestone Pharmaceuticals by 186.2% during the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company's stock worth $5,666,000 after purchasing an additional 1,842,974 shares during the last quarter. Marshall Wace LLP increased its position in shares of Milestone Pharmaceuticals by 289.8% during the 4th quarter. Marshall Wace LLP now owns 1,656,821 shares of the company's stock worth $3,347,000 after purchasing an additional 1,231,793 shares during the last quarter. Finally, Pathstone Holdings LLC acquired a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter worth about $2,000,000. Institutional investors and hedge funds own 86.18% of the company's stock.
Milestone Pharmaceuticals Company Profile
(
Get Free Report)
Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company's research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone's pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.
Milestone's lead product candidates are delivered through inhalation or systemic administration, reflecting the company's commitment to optimizing therapeutic delivery directly to the lungs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
